Jaroslav Čermák
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jaroslav Čermák has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Kyra Michalova
Institute of Hematology and Blood Transfusion, Prague, Czech Republic
6 shared publications - Zuzana Zemanova
Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine of Charles University in Prague, Prague, Czech Republic
4 shared publications - Anna Jonasova
General University Hospital, 128 08 Prague, Czech Republic
2 shared publications Jana Březinová
2 shared publicationsJana Vondrakova
2 shared publicationsRadana Neuwirtova
2 shared publications
Latest Publications
- Open Access
- 16 May 2025
- Published by Solen s.r.o. in Vnitrni Lekarstvi
- Vol. 71 (3) , E1-E6
Treatment of paroxysmal nocturnal hemoglobinuria patients with complement inhibitors
C?l: Paroxyzm?ln? no?n? hemoglobinurie (PNH) p?edstavuje vz?cn?, ale z?va?n? onemocn?n? krvetvorby zp?soben? nedostatkem p?irozen?ch inhibitor? aktivace komplementu na povrchu bun?k projevuj?c? se intravaskul?rn? hemol?zou, trombotick?mi kompl... C?l: Paroxyzm?ln? no?n? hemoglobinurie (PNH) p?edstavuje vz?cn?, ale z?va?n? onemocn?n? krvetvorby zp?soben? nedostatkem p?irozen?ch inhibitor? aktivace komplementu na povrchu bun?k projevuj?c? se intravaskul?rn? hemol?zou, trombotick?mi kompl...
- 16 May 2025
- Published by Solen s.r.o. in Vnitrni Lekarstvi
- Vol. 71 (3) , E1-E6
Open AccessTreatment of paroxysmal nocturnal hemoglobinuria patients with complement inhibitors
C?l: Paroxyzm?ln? no?n? hemoglobinurie (PNH) p?edstavuje vz?cn?, ale z?va?n? onemocn?n? krvetvorby zp?soben? nedostatkem p?irozen?ch inhibitor? aktivace komplementu na povrchu bun?k projevuj?c? se intravaskul?rn? hemol?zou, trombotick?mi kompl... C?l: Paroxyzm?ln? no?n? hemoglobinurie (PNH) p?edstavuje vz?cn?, ale z?va?n? onemocn?n? krvetvorby zp?soben? nedostatkem p?irozen?ch inhibitor? aktivace komplementu na povrchu bun?k projevuj?c? se intravaskul?rn? hemol?zou, trombotick?mi kompl...
- Open Access
- 9 September 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1420666
Case report: Development of clonal hematologic disorders from inherited bone marrow failure
Introduction: Inherited bone marrow failure (IBMF) syndromes are caused by mutations forming pathologic germline variants resulting in the production of defective hematopoietic stem cells (HSC) and in congenital failure in the production of one or more blood lineages. An acquisition of subsequent somatic mutations is determining further course of the disease. Nevertheless, a certain number of patients with IBMF may escape correct diagnosis in childhood, especially those with mild cytopenia and minimal clinical features without non-hematologic symptoms. These patients usually present in the third decade of life with unexplained cytopenia or myelodysplastic syndrome (MDS).Methods and results: We report 2 patients with IBMF who were correctly diagnosed between 20 and 40 years of age when they were referred with progressive MDS with adverse prognostic factors that affected their outcome.Discussion: IBMF syndromes should be excluded in all patients below 40 years of age with unexplained cytopenia. Early hematopoietic stem cell transplantation (HSCT) is the treatment of choice in these patients.
- 9 September 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1420666
Open AccessCase report: Development of clonal hematologic disorders from inherited bone marrow failure
Introduction: Inherited bone marrow failure (IBMF) syndromes are caused by mutations forming pathologic germline variants resulting in the production of defective hematopoietic stem cells (HSC) and in congenital failure in the production of one or more blood lineages. An acquisition of subsequent somatic mutations is determining further course of the disease. Nevertheless, a certain number of patients with IBMF may escape correct diagnosis in childhood, especially those with mild cytopenia and minimal clinical features without non-hematologic symptoms. These patients usually present in the third decade of life with unexplained cytopenia or myelodysplastic syndrome (MDS).Methods and results: We report 2 patients with IBMF who were correctly diagnosed between 20 and 40 years of age when they were referred with progressive MDS with adverse prognostic factors that affected their outcome.Discussion: IBMF syndromes should be excluded in all patients below 40 years of age with unexplained cytopenia. Early hematopoietic stem cell transplantation (HSCT) is the treatment of choice in these patients.
- 1 December 2015
- Vol. 61 (12) , 1028-33
[Lenalidomide treatment in myelodysplastic syndrome with 5q deletion--Czech MDS group experience].
Myelodysplastic syndrome (MDS) is a common hematological disease in patients over sixty. Despite intensive research, the therapy of this heterogeneous blood disease is complicated. In recent years, two new therapeutic approaches have been proposed: immunomodulation and demethylation therapy. Immunomodulation therapy with lenalidomide represents a meaningful advance in the treatment of anemic patients, specifically those with 5q- aberrations. As much as 60-70% of patients respond and achieve transfusion independence. We present the initial lenalidomide experience of the Czech MDS group. We analyze Czech MDS register data of 34 (31 female; 3 male; median age 69 years) chronically transfused low risk MDS patients with 5q- aberration treated by lenalidomide. Twenty-seven (79.4%) patients were diagnosed with 5q- syndrome, 5 patients with refractory anemia with multilineage dysplasia, 1 patient with refractory anemia with excess of blasts 1, and 1 patient with myelodysplastic/myeloproliferative unclassified. Response, as represented by achieving complete transfusion independence, was achieved in 91% of patients. A true 5q- syndrome diagnosis in most our patients may be responsible for such a high response rate. Complete cytogenetic response was reached in 15% of patients and partial cytogenetic response in 67%, within a median time of 12 months. TP53 mutation was detected in 15% (3 from 18 tested) and 2 of these patients progressed to higher grade MDS. The majority of patients tolerated lenalidomide very well. Based on this albeit small study, we present our findings of high lenalidomide efficacy as well as the basic principles and problems of lenalidomide therapy.
- 1 December 2015
- Vol. 61 (12) , 1028-33
[Lenalidomide treatment in myelodysplastic syndrome with 5q deletion--Czech MDS group experience].
Myelodysplastic syndrome (MDS) is a common hematological disease in patients over sixty. Despite intensive research, the therapy of this heterogeneous blood disease is complicated. In recent years, two new therapeutic approaches have been proposed: immunomodulation and demethylation therapy. Immunomodulation therapy with lenalidomide represents a meaningful advance in the treatment of anemic patients, specifically those with 5q- aberrations. As much as 60-70% of patients respond and achieve transfusion independence. We present the initial lenalidomide experience of the Czech MDS group. We analyze Czech MDS register data of 34 (31 female; 3 male; median age 69 years) chronically transfused low risk MDS patients with 5q- aberration treated by lenalidomide. Twenty-seven (79.4%) patients were diagnosed with 5q- syndrome, 5 patients with refractory anemia with multilineage dysplasia, 1 patient with refractory anemia with excess of blasts 1, and 1 patient with myelodysplastic/myeloproliferative unclassified. Response, as represented by achieving complete transfusion independence, was achieved in 91% of patients. A true 5q- syndrome diagnosis in most our patients may be responsible for such a high response rate. Complete cytogenetic response was reached in 15% of patients and partial cytogenetic response in 67%, within a median time of 12 months. TP53 mutation was detected in 15% (3 from 18 tested) and 2 of these patients progressed to higher grade MDS. The majority of patients tolerated lenalidomide very well. Based on this albeit small study, we present our findings of high lenalidomide efficacy as well as the basic principles and problems of lenalidomide therapy.
- 1 December 2013
- Published by Elsevier in Leukemia Research
- Vol. 37 (12) , 1612-1615
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes
- 1 December 2013
- Published by Elsevier in Leukemia Research
- Vol. 37 (12) , 1612-1615
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes
- 20 May 2011
- Published by Taylor & Francis in Hemoglobin
- Vol. 35 (3) , 217-227
Efficacy And Safety Of Administration Of Oral Iron Chelator Deferiprone In Patients With Early Myelodysplastic Syndrome
Forty-eight patients with early myelodysplastic syndrome (MDS) without excess of blasts, with average initial serum ferritin levels of 2739.5 μg/L (range 825–11287 μg/L), were treated with deferiprone (L1) in a daily dose of 40–90 mg/kg. Median duration of chelation treatment was 10.9 months (range 4–24 months). Chelation was effective (maintained or decreased iron stores) in 16 out of 22 patients (73%) with serum ferritin levels 2000 μg/L. Combination of L1 with recombinant human erythropoietin (rHuEPO) (30–40 kU/week) resulted in effective chelation in five additional patients with serum ferritin levels >3000 μg/L. Incidence of adverse effects was comparable to that in thalassemic patients. Gastrointestinal symptoms represented the most frequent adverse effect of L1 therapy (37.5% of patients) that limited an effective escalation of the daily dose of the drug and led to discontinuation of the treatment for six patients. A decreased number of granulocytes was observed in five (13%) patients and agranulocytosis occurred in two patients (4%). Granulocyte counts were restored after cessation of L1 treatment and administration of granulocyte colony stimulating factor (G-CSF) in all but one patient. Administration of L1 in a daily dose of at least 75 mg/kg may represent an alternative approach in treatment of mild and moderate iron overload in MDS patients who cannot be treated with deferasirox (DFRA) or deferoxamine (DFO).
- 20 May 2011
- Published by Taylor & Francis in Hemoglobin
- Vol. 35 (3) , 217-227
Efficacy And Safety Of Administration Of Oral Iron Chelator Deferiprone In Patients With Early Myelodysplastic Syndrome
Forty-eight patients with early myelodysplastic syndrome (MDS) without excess of blasts, with average initial serum ferritin levels of 2739.5 μg/L (range 825–11287 μg/L), were treated with deferiprone (L1) in a daily dose of 40–90 mg/kg. Median duration of chelation treatment was 10.9 months (range 4–24 months). Chelation was effective (maintained or decreased iron stores) in 16 out of 22 patients (73%) with serum ferritin levels 2000 μg/L. Combination of L1 with recombinant human erythropoietin (rHuEPO) (30–40 kU/week) resulted in effective chelation in five additional patients with serum ferritin levels >3000 μg/L. Incidence of adverse effects was comparable to that in thalassemic patients. Gastrointestinal symptoms represented the most frequent adverse effect of L1 therapy (37.5% of patients) that limited an effective escalation of the daily dose of the drug and led to discontinuation of the treatment for six patients. A decreased number of granulocytes was observed in five (13%) patients and agranulocytosis occurred in two patients (4%). Granulocyte counts were restored after cessation of L1 treatment and administration of granulocyte colony stimulating factor (G-CSF) in all but one patient. Administration of L1 in a daily dose of at least 75 mg/kg may represent an alternative approach in treatment of mild and moderate iron overload in MDS patients who cannot be treated with deferasirox (DFRA) or deferoxamine (DFO).
- 30 November 2009
- Published by Elsevier in Leukemia Research
- Vol. 33 (11) , 1469-1474
Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts
- 30 November 2009
- Published by Elsevier in Leukemia Research
- Vol. 33 (11) , 1469-1474
Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts
- 15 July 2007
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 176 (2) , 150-155
Molecular cytogenetic analysis of complex karyotypes with derivative chromosome der(1)t(1;5) found in two patients with myeloid leukemia
- 15 July 2007
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 176 (2) , 150-155
Molecular cytogenetic analysis of complex karyotypes with derivative chromosome der(1)t(1;5) found in two patients with myeloid leukemia
- 1 January 2006
- Published by Taylor & Francis in Hemoglobin
- Vol. 30 (1) , 105-112
Erythropoietin Administration May Potentiate Mobilization of Storage Iron in Patients on Oral Iron Chelation Therapy
Five, repeatedly transfused, patients with refractory anemia (RA) or RA with ringed sideroblast (RARS) subtypes of myelodysplastic syndrome (MDS), with serum ferritin (SF) levels of >2,000 μg/L, and one female with Hb E [β26(B8)Glu→Lys]/β0-thalassemia (thal) with an SF level of 1,760 μg/L, were treated with deferiprone (L1) at the dose of 4–6 g per day for at least 26 months. Beginning in the second month, all patients received recombinant human erythropoietin (rHuEPO) at the dose of 150 IU/kg thrice weekly, subcutaneously for 24 months. A significant increase in iron excretion after combined administration of L1 and rHuEPO compared to treatment with L1 as a single agent, was observed in all patients. The amount of excreted iron in urine ranged from 7.5 to almost 20 mg per day. In one patient, a response to rHuEPO resulted in transfusion independence and her SF decreased from 2086 to 879 μg/L. In four MDS patients, who remained dependent on red blood cell (RBC) transfusions, simultaneous administration of L1 and rHuEPO enabled the stabilization of SF levels, despite continuing iron load from the transfusions. Combined administration of rHuEPO and oral iron chelators may potentiate mobilization of storage iron and maintain iron balance in transfusion-dependent iron overloaded early MDS patients.
- 1 January 2006
- Published by Taylor & Francis in Hemoglobin
- Vol. 30 (1) , 105-112
Erythropoietin Administration May Potentiate Mobilization of Storage Iron in Patients on Oral Iron Chelation Therapy
Five, repeatedly transfused, patients with refractory anemia (RA) or RA with ringed sideroblast (RARS) subtypes of myelodysplastic syndrome (MDS), with serum ferritin (SF) levels of >2,000 μg/L, and one female with Hb E [β26(B8)Glu→Lys]/β0-thalassemia (thal) with an SF level of 1,760 μg/L, were treated with deferiprone (L1) at the dose of 4–6 g per day for at least 26 months. Beginning in the second month, all patients received recombinant human erythropoietin (rHuEPO) at the dose of 150 IU/kg thrice weekly, subcutaneously for 24 months. A significant increase in iron excretion after combined administration of L1 and rHuEPO compared to treatment with L1 as a single agent, was observed in all patients. The amount of excreted iron in urine ranged from 7.5 to almost 20 mg per day. In one patient, a response to rHuEPO resulted in transfusion independence and her SF decreased from 2086 to 879 μg/L. In four MDS patients, who remained dependent on red blood cell (RBC) transfusions, simultaneous administration of L1 and rHuEPO enabled the stabilization of SF levels, despite continuing iron load from the transfusions. Combined administration of rHuEPO and oral iron chelators may potentiate mobilization of storage iron and maintain iron balance in transfusion-dependent iron overloaded early MDS patients.
- 1 April 2005
- Published by Elsevier in Leukemia Research
- Vol. 29 (4) , 371-379
The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia
- 1 April 2005
- Published by Elsevier in Leukemia Research
- Vol. 29 (4) , 371-379
The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia